An ambitious new EU-funded research initiative, EU-RESPONSE, will establish a clinical research network to treat COVID-19 and other emerging infectious diseases. The Commission announced today that it will support the project with €15.7 million.
The funds are mobilised from the Horizon 2020 research and innovation programme as part of the Commission’s €1 billion pledge for coronavirus research and innovation, announced by President Ursula von der Leyen in May.
Mariya Gabriel, Commissioner for Innovation, Research, Culture, Education and Youth said:
“EU-RESPONSE is a major step towards pan-European clinical trials that not only give us the scale we need to rapidly assess potential treatments, but can also adapt rapidly as new facts and ideas emerge. This EU clinical trials network will serve Europe now to address COVID-19 and help us prepare for future threats by offering speed, scale and solidarity.”
ECRIN will play a role in the three key objectives of the EU-RESPONSE project, funded by the European Union and coordinated by INSERM.
The first goal is the expansion of DisCoVeRy, a phase III, adaptive randomised, controlled multicentre clinical trial designed to evaluate the efficacy of repurposing medication in hospitalised adult patients diagnosed with COVID-19 to other European countries (Austria, Belgium, Czech Republic, France, Greece, Hungary, Italy, Luxemburg, Norway, Poland, Portugal, Slovakia, Spain, Switzerland, Turkey).
Upon completion of the DisCoVeRy trial, a new multinational adaptive European COVID-19 and emerging infectious diseases platform trial network will be built and implemented.
The final objective includes the coordination module with the EU-funded RECOVER project, and in particular with the REMAP-COVID trial, to ensure complementarity and cooperation across all the large European COVID-19 Adaptive Platform trials and their capacity to answer the needs of society through dialogue with the EMA, national competent authorities, HTAs and Industry partners. This coordination module is led by ECRIN, and also includes a toolbox to design and manage adaptive platform trials: https://ecrin.org/news/eu-response-new-tool-ecrins-arsenal-fight-covid-19
Access the FACTS SHEET
The articles can be sorted by therapeutic area or disease, but may also deal with more general topics not specifically related to a disease. These articles can be sorted as "other".